RespireRx Pharmaceuticals Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RSPI research report →
Companywww.respirerx.com
RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors.
- CEO
- Arnold S. Lippa
- IPO
- 1989
- Employees
- 2
- HQ
- Glen Rock, NJ, US
Price Chart
Valuation
- Market Cap
- $657.75K
- P/E
- -0.10
- P/S
- 0.00
- P/B
- -0.02
- EV/EBITDA
- -2.04
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 19.21%
- ROIC
- 16.88%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-2,102,720 · 45.66%
- EPS
- $-0.04 · 10.53%
- Op Income
- $-1,579,355
- FCF YoY
- 84.95%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.61
- Avg Volume
- 30.10K
Get TickerSpark's AI analysis on RSPI
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 30, 20 | Dickason David | other | 2,000,000 |
| Sep 30, 20 | Jones Timothy L. | other | 4,409,063 |
| Sep 30, 20 | Jones Timothy L. | other | 4,409,063 |
| Sep 30, 20 | Jones Timothy L. | other | 4,409,063 |
| Sep 30, 20 | Jones Timothy L. | other | 4,409,063 |
| Sep 30, 20 | Jones Timothy L. | other | 28.218 |
| Sep 30, 20 | Jones Timothy L. | other | 28.218 |
| Sep 30, 20 | Jones Timothy L. | other | 28.218 |
| Sep 30, 20 | Jones Timothy L. | other | 28.218 |
| Sep 30, 20 | MacFarlane Katie | other | 5,000,000 |
Our RSPI Coverage
We haven't published any research on RSPI yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RSPI Report →